FDA Approval Alert: The Need-to-Know | Nirogacestat in Desmoid Tumors

In November 2023, the FDA approved nirogacestat as a treatment for patients with progressing desmoid tumors that require systemic therapeutics.

The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
Nirogacestat Approval Offers Choice to Desmoid Tumor Population
Video
Nov 28, 2023 9:00 PM
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
Patients with desmoid tumors can now receive nirogacestat following the FDA’s approval of the agent.
FDA OKs Nirogacestat for Treatment of Desmoid Tumors
Article
Nov 27, 2023 10:47 PM
Patients with desmoid tumors can now receive nirogacestat following the FDA’s approval of the agent.